13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001931118
Total reported value
$158.4M
$158.4M
38 檔
32.8%
According to the latest 13F quarterly dataset, Superstring Capital Management LP managed an equity portfolio of $158.4M at the end of Q4 2024, spanning 38 distinct U.S. exchange-listed positions.
During Q4 2024, Superstring Capital Management LP's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 12.44% | +1.74% | +87.54% | |
| 2 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 9.69% | — | +49.83% | |
| 3 | ZLAB | Zai Lab Ltd-adr | Stock-Other | 9.15% | -1.84% | -44.47% | |
| 4 | NVCR | NovoCure Limited | Stock-Healthcare | 7.41% | — | -26.93% | |
| 5 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 6.23% | — | +15.64% | |
| 6 | COGT | Cogent Biosciences Inc | Stock-Other | 6.15% | +2.20% | — | |
| 7 | CYTK | Cytokinetics Inc | Stock-Healthcare | 5.27% | — | -40.04% | |
| 8 | GPCR | Structure Therapeutics Inc | Stock-Other | 5.09% | — | -4.51% | |
| 9 | IDYA | Ideaya Biosciences Inc | Stock-Other | 5.05% | — | — | |
| 10 | URGN | UroGen Pharma Ltd. | Stock-Other | 2.78% | -0.53% | — | |
| 11 | SMMT | Summit Therapeutics Inc | Stock-Other | 2.54% | -12.09% | EXIT | |
| 12 | TIL | Instil Bio Inc | Stock-Other | 2.45% | — | +37.63% | |
| 13 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 2.30% | — | — | |
| 14 | INSM | Insmed Inc | Stock-Healthcare | 2.15% | — | — | |
| 15 | FATE | Fate Therapeutics Inc | Stock-Other | 1.97% | — | -5.96% | |
| 16 | LEGN | Legend Biotech Corp-adr | Stock-Other | 1.96% | — | +15.00% | |
| 17 | TARA | Protara Therapeutic Inc | Stock-Other | 1.65% | -0.16% | — | |
| 18 | CABA | Cabaletta Bio Inc | Stock-Other | 1.62% | +0.15% | +523.92% | |
| 19 | DYN | Dyne Therapeutics Inc | Stock-Other | 1.49% | — | — | |
| 20 | SVRA | Savara Inc | Stock-Other | 1.35% | -2.39% | +154.17% | |
| 21 | TNGX | Tango Therapeutics Inc | Stock-Other | 1.27% | — | -20.71% | |
| 22 | KURA | Kura Oncology Inc | Stock-Other | 1.19% | — | — | |
| 23 | INCY | Incyte CORP | Stock-Healthcare | 1.08% | — | — | |
| 24 | ONC | Beone Medicines Ltd-adr | Stock-Other | 1.02% | +2.21% | NEW | |
| 25 | VSTM | Verastem Inc | Stock-Other | 0.94% | — | — | |
| 26 | ETNBGBP | 89bio Inc | Stock-Other | 0.90% | — | -77.66% | |
| 27 | ZBIO | Zenas Biopharma Inc | Stock-Other | 0.79% | — | — | |
| 28 | CAPR | Capricor Therapeutics Inc | Stock-Other | 0.66% | — | -83.63% | |
| 29 | KYTX | Kyverna Therapeutics Inc | Stock-Other | 0.59% | — | — | |
| 30 | RZLT | Rezolute Inc | Stock-Other | 0.52% | — | — | |
| 31 | IPSC | Century Therapeutics Inc | Stock-Other | 0.40% | -0.19% | EXIT | |
| 32 | ✓ | Zura Bio LTD | Stock-Other | 0.40% | — | +19.36% | |
| 33 | EYPT | Eyepoint Inc | Stock-Other | 0.32% | — | — | |
| 34 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 0.31% | +6.98% | — | |
| 35 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 0.30% | — | — | |
| 36 | LXEO | Lexeo Therapeutics Inc | Stock-Other | 0.30% | — | — | |
| 37 | CLYM | Climb Bio Inc | Stock-Other | 0.15% | +3.32% | +190.21% | |
| 38 | ✓ | Stock-Other | 0.09% | — | — |
According to official SEC Form 13F filings, Superstring Capital Management LP reported a total U.S. public equity portfolio value of $158.4M across 38 disclosed positions in Q4 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including ORIC, 430, ZLAB) accounted for 32.8% of total reported equity market value during Q4 2024.
During Q4 2024, Superstring Capital Management LP's top holdings by market value included ORIC (12.4%)、430 (9.7%)、ZLAB (9.2%). The largest single position, ORIC, represented 12.4% of total portfolio value.
In Q4 2024, Superstring Capital Management LP made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.